Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions.
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms VIDA
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Apr 2011 Planned end date changed from May 2012 to Jun 2013 as reported by ClinicalTrials.gov.